To　summarize　the　experience　in　intraarterial　neoadjuvant　chemotherapy　for　extremity　osteosarcoma.　Between　January　2002　and　December　2007,111　patients　with　stage　IIB　extremity　osteosarcoma　received　preoperative　intraarterial　therapy　with　subcutaneous　implantation　of　chemotherapy　pump　as　well　as　en　bloc　resection,　and　postoperative　adjuvant　chemotherapy.　There　were　63　males　and　48　females　with　an　average　age　of　18　(range,　14　similar　to　39　years).　The　time　from　symptom　onset　to　hospitalization　varied　from　several　days　to　6　months.　The　induction　chemotherapy　regimen　includes:　epirubicin　[50　similar　to　70　mg/m(2)　by　4-hour　intraarterial　infusion/day　for　3　day]　and　cisplatin　[100　similar　to　120　mg/m(2)　by　2-hour　intraarterial　infusion/day　for　3　days]　repetitively　every　2　similar　to　3　weeks.　Among　which　24　cases　only　received　two　cycles　induction　chemotherapy　was　set　to　nonstandard　chemotherapy　group　and　87　cases　received　three　to　six　cycles　induction　chemotherapy　set　to　standard　chemotherapy　group.　The　number　of　preoperative　chemotherapy-cycles　of　standard　chemotherapy　group　depends　on　the　clinical　and　radiographic　evaluation　of　chemotherapy　efficacy.　Median　follow-up　time　was　28(8　similar　to　48)　months.　The　rate　of　limb　preservation　surgery　was　89.53%　(77/86)　in　standard　chemotherapy　group,and　was　37.5%　(9/24)　in　nonstandard　chemotherapy　group.　Kaplan-Meier　survival　analysis　showed　that　the　3-year　overall　survival　rate　and　disease　free　survival　rate　of　all　the　111　cases　were　68.3%　and　65.9%　respectively.　There　were　significant　differences　in　overall　survival　rate　(38.9%,　80.0%,　P　=　0.000),　disease　free　survival　rate　(30.1%,　79.5%,　P　=　0.000),　distant　metastasis　rate　(66.67%,　16.09%,　P　=　0.0000)　and　local　recurrence　rate　(58.33%,　13.79%,　P　=　0.0000)　between　nonstandard　chemotherapy　group　and　standard　chemotherapy　group.　Standard　intraarterial　neo-adjuvant　chemotherapy　was　more　effective　than　nonstandard　intraarterial　induction　chemotherapy　to　stage　IIB　extremity　osteosarcoma.